DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally.
Show moreShow less
The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products.
The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands.
The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
Quality Score breakdown
Overall quality38/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability25
How much profit the company makes from its sales and capital
Quality Growth39
Are margins and returns getting better?
Cashflow4
Do the profits arrive as real cash?
Financial strength49
Debt, balance sheet and risk of trouble
Investment91
Does it invest with discipline instead of growing at any price?
Low Volatility2
How calm the share price moves, does not count
Price momentum100
Price momentum of the last 3 to 12 months, does not count
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+10.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Start year 2020 (pandemic). Over 10 years: +3.0% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.0% (2020) → −7.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 49 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Bottom 25%
Profitability
Return on assets−16.3% · Bottom 25%
Net margin (12 months)−10.7% · Bottom 25%
Operating margin (12 months)−6.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)14.9% · Top 25%
Balance sheet
Debt / equity0.61× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/B2.09× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
DocMorris AG has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of DocMorris AG (DOCM)?
DocMorris AG reported trailing-twelve-month revenue of about CHF 1.2B (latest available figure, as of Sep 13, 2026).
How solid is the balance sheet of DocMorris AG (DOCM)?
Balance-sheet figures for DocMorris AG (as of Sep 13, 2026): return on equity −30.1%, debt of 0.61 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
Which stocks are comparable to DocMorris AG?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of DocMorris AG (DOCM)?
The closing price on Nov 9, 2026 was CHF 17.47. We carry closing prices from our data provider, not a live tick.
Key figures of DocMorris AG
How large is the market capitalisation of DocMorris AG (DOCM)?
The market capitalisation of DocMorris AG is CHF 854M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DocMorris AG (DOCM)?
The price-to-sales ratio of DocMorris AG is 0.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DocMorris AG (DOCM)?
Earnings per share at DocMorris AG are CHF −2.46. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of DocMorris AG (DOCM)?
The net margin of DocMorris AG is −10.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DocMorris AG (DOCM)?
The return on equity (ROE) of DocMorris AG is −30.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DocMorris AG (DOCM)?
On an EBIT basis the return on assets of DocMorris AG is −8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DocMorris AG (DOCM)?
The operating margin of DocMorris AG is −6.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DocMorris AG (DOCM)?
Revenue at DocMorris AG is growing +14.9% versus a year earlier (3y avg +6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does DocMorris AG (DOCM) generate?
The free cash flow of DocMorris AG is −CHF 90.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DocMorris AG (DOCM) carry?
The net debt of DocMorris AG is CHF 169M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DocMorris AG in the live analysis
One click puts DocMorris AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Sep 13, 2026